Апр
18,
2019
Апр 18, 2019
The launch of PMBL® tablets in two countries :
Lallemand pharma is pleased to announce its partnership with UniMed UniHealth Pharmaceuticals Ltd, distributor and manufacturer of our PMBL® tablets distributed under Ismigen® brand in Bangladesh. UniMed UniHealth introduced life-saving and innovative pharmaceutical products since 1997. The active substance, Polyvalent Mechanical Bacterial Lysate, is manufactured in France by Lallemand. This drug is indicated in the prevention of respiratory tract infections.
Following the launch in October 2018 Pr Guido Ferlazzo, MD (Professor of General Immunology and Pathology — University of Messina, Italy) spoke about an additional mechanism of action of PMBL® tablets in a scientific seminar organized in Bangladesh on February 17th-18th 2019. (see more in the Expertise section of this newsletter).
As a distributor and marketer of pharmaceutical products of well-known selected companies from around the world, Healol became the new distributor of Lallemand Pharma in Thailand.
In the frame of this partnership, Maxence de Villemeur, Global Marketing & Sales Manager in Lallemand Pharma, ensured the Marketing and Scientific training of Thai Healol Medical Representatives team in December 4th 2018. Lallemand Pharma is now pleased to announce the launch of our product Ismigen in Thailand in January 2019.
Forthcoming event :
The EAACI (European Academy of Allergy and Clinical Immunology) Congress 2019 in Lisbon, Portugal will help all attending delegates and participants to advance their knowledge and navigate the complex world of today’s allergy and clinical immunology. In the frame of this congress, Pr Janeczek (Department of Children’s Lung Diseases and Rheumatology in Poland) will give a lecture about « PMBL in allergic rhinitis children », on June 3rd.
Business development in Latin America :
Lallemand Pharma reinforces its business development entering into agreement with a local agent in Latin America, with long and acute experience in pharmaceutical organizations. For any further information, please contact Lallemand Pharma.